Skip to main content

Advertisement

Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib

Fig. 2

In vitro sustained release of drugs from PLGA-PEG NPs. The non-modified drug-loaded NPs and LFC131-conjugated drug-loaded NPs showed relatively fast drug release in the initial 24 h followed by sustained release patterns over a period of 192 h in PBS at pH 7.4 and pH 5.5. a Sora-NPs and LFC-Sora-NPs; b Meta-NPs and LFC-Meta-NPs. Data are expressed as the mean ± SD (n = 3)

Back to article page